GCL : E Be part of history in the making. AstraZeneca is building its first biologics manufacturing campus in Singapore — a groundbreaking USD 1.5 billion investment that will serve as a global hub for innovation and excellence. This state-of-the-art facility will deliver end-to-end Antibody-Drug Conjugate (ADC) capabilities with different manufacturing units/buildings in one campus Small molecule- chemical API production Large molecule- monoclonal antibody manufacturing Conjugation Fill-and-finish operations, including sterile filling and lyophilization Final secondary packaging
The campus will be equipped with modern digital and automation infrastructure, enabling autonomous manufacturing powered by artificial intelligence. In addition, it will be designed for carbon neutrality, embedding sustainability into every aspect of operations and setting a new benchmark for environmentally responsible biologics manufacturing. We are looking for passionate individuals with relevant experie...